Koselugo under the microscope: Real-World data on nerve tumor drug
NCT ID NCT06360406
First seen Nov 01, 2025
Summary
This study tracks how well the drug Koselugo (selumetinib) works and what side effects it causes in people with Neurofibromatosis Type 1 and painful nerve tumors. About 200 patients in South Korea will be followed during their normal doctor visits. The goal is to confirm the drug's safety and effectiveness in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
RECRUITINGChungcheongbuk-do, South Korea
-
Research Site
RECRUITINGDaejeon, South Korea
-
Research Site
RECRUITINGGyeonggi-do, South Korea
-
Research Site
RECRUITINGIncheon, South Korea
-
Research Site
RECRUITINGJeonnam, South Korea
-
Research Site
SUSPENDEDSeoul, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
COMPLETEDSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGWŏnju, South Korea
-
Research Site
RECRUITINGYangsan, South Korea
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.